CBUS CIBUS INC

Cibus to Report Third Quarter 2023 Financial Results on November 9, 2023 and Host Conference Call

Cibus to Report Third Quarter 2023 Financial Results on November 9, 2023 and Host Conference Call

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a global leader in gene editing in agriculture and the development of productivity traits in plants, today announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Title: Cibus, Inc. Third Quarter 2023 Results Conference Call

Event Date: Thursday, November 9, 2023

Time: 4:30 p.m. ET

Participant Numbers: (U.S.), (International)

Event Link:

For interested individuals unable to join the conference call, a dial-in replay of the call will be available through Thursday, November 23, 2023 and can be accessed by dialing (U.S.), (International) and entering replay passcode: 22028314.

A live audio webcast of the call, along with accompanying slides, will be available under "News & Events” in the Investor section of the Company's website, investor.cibus.com. An archived webcast will be available on the Company's website for 90 days after the event.

About Cibus

Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability areas for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that develops and licenses traits to leading seed companies. Cibus’ focus is developing scale, multi-crop traits in the major global crops such as canola, rice, and soybean. Traits that can make a real impact in global agricultural productivity. Cibus is the technology leader in high throughput gene editing technology with its Trait Machine™ process. It enables Cibus to develop plant traits precisely and predictably at a fraction of the time and cost of conventional breeding. Cibus has developed a pipeline of five productivity traits including important traits for pod shatter reduction, disease resistance, and weed management. Its initial traits for pod shatter reduction and weed management are developed and are in commercial collaborations with leading seed companies. Its other pipeline traits, including Sclerotinia resistance, are in advanced greenhouse and field trial stages.

Cibus Contacts:

Investor Relations

Karen Troeber

858-450-2636

Jeff Sonnek – ICR

Media Relations

Colin Sanford



203-918-4347



EN
02/11/2023

Underlying

CBUSCIBUS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CIBUS INC

 PRESS RELEASE
Free
CBUS CIBUS INC

USDA Designates Cibus’ Herbicide Tolerance Canola Trait HT2 as Not Reg...

USDA Designates Cibus’ Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA’s Biotechnology Regulations This action follows the USDA’s recent designation of Cibus’ disease resistance traits in Canola as not regulated, continuing Cibus’ product development momentum in the globally important Canola crop SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that its most recent trait for its herbicide tolerance trait (HT2) in Ca...

22h / 1m 1 EN
 PRESS RELEASE
Free
CBUS CIBUS INC

Cibus, Inc. Announces Pricing of $27.5 Million Public Offering

Cibus, Inc. Announces Pricing of $27.5 Million Public Offering SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus’ board of directors ...

June 5, 2025 1 EN
 PRESS RELEASE
Free
CBUS CIBUS INC

Cibus, Inc. Announces Proposed Public Offering

Cibus, Inc. Announces Proposed Public Offering SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock (or common stock equivalents in lieu thereof) in a public offering. All of the securities to be sold in the offering are to be offered by Cibus. The Chairman of Cibus’ board of directors, Mr. Rory Riggs, has...

June 4, 2025 1 EN
 PRESS RELEASE
Free
CBUS CIBUS INC

Cibus Provides Webcast of BofA Securities AgTech Virtual Conference Fi...

Cibus Provides Webcast of BofA Securities AgTech Virtual Conference Fireside Chat SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President and Interim Chief Executive Officer, participated in the BofA Securities 2025 AgTech Virtual Conference this week. During the fireside chat, hosted by BofA research analyst Stephen Byrne, management di...

May 27, 2025 1 EN
 PRESS RELEASE
Free
CBUS CIBUS INC

Cibus to Participate in Alliance Global Partner’s Annual Virtual Healt...

Cibus to Participate in Alliance Global Partner’s Annual Virtual Healthcare Company Showcase SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will host a presentation at the AGP Annual Virtual Healthcare Company Showcase. During the presentation, Dr. Beetham will discuss the Company's progress...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch